Huntington's Disease Genetic Variants encompass the spectrum of pathogenic changes in the HTT gene that cause Huntington's disease (HD), an autosomal dominant neurodegenerative disorder. Unlike most neurodegenerative diseases, HD has a single deterministic genetic cause—a CAG trinucleotide repeat expansion in the HTT gene. This genetic simplicity makes HD a unique model for understanding disease mechanisms and developing therapies.
¶ Gene Structure and Function
The HTT gene (also known as IT15 - "interesting transcript 15") is located on chromosome 4p16.3 and encodes huntingtin, a large protein of 3,144 amino acids. Huntingtin is essential for normal development and is expressed ubiquitously in the brain and peripheral tissues.
Wild-type huntingtin plays important roles in:
- Neuronal development: Essential for embryonic neurogenesis
- Synaptic function: Regulates vesicle trafficking and neurotransmitter release
- Transcriptional regulation: Supports neuronal survival through gene expression control
- Axonal transport: Facilitates organelle and protein trafficking
- Autophagy: Participates in cellular quality control mechanisms
HD is caused by an unstable CAG trinucleotide repeat expansion in the first exon of the HTT gene. This expansion leads to a mutant huntingtin protein with an elongated polyglutamine tract that forms toxic aggregates.
| CAG Repeats |
Disease Status |
Age of Onset |
Clinical Implications |
| < 27 |
Normal |
N/A |
No disease risk |
| 27-35 |
Intermediate |
N/A |
Not disease-causing, but may expand in offspring (anticipation) |
| 36-39 |
Reduced penetrance |
Variable |
May or may not develop HD; onset often later |
| 40-50 |
Full penetrance |
~60 years |
Will develop HD |
| 51-90 |
Full penetrance |
~40 years |
Earlier onset, more rapid progression |
| > 90 |
Full penetrance |
~20 years |
Juvenile HD (Westphal variant) |
The disease demonstrates anticipation—a phenomenon where successive generations present with earlier onset. This is primarily due to:
- Paternal transmission bias: Paternal repeats are more unstable, especially during spermatogenesis
- Repeat expansion: The repeat tends to increase when passed to offspring
- Maternal effects: Maternal transmission is more stable but expansion can still occur
When onset occurs before age 20, the disease is termed "juvenile HD" or Westphal variant. Key features include:
- Motor presentation: Predominant bradykinesia and rigidity (rather than chorea)
- Seizures: Occur in approximately 30% of cases
- Rapid progression: More aggressive disease course
- Repeat length: Usually associated with > 60 CAG repeats
While HTT is the causative gene, several genetic modifiers influence age of onset and disease progression:
Variants in DNA repair genes can significantly modify the disease phenotype:
- MSH3: Somatic expansion modifier; variants affect rate of repeat expansion in tissues
- MUTYH: Base excision repair gene; variants influence onset age
- POLD2: DNA polymerase delta; impacts repeat stability
- LIG1: DNA ligase I; recent studies show variants can suppress CAG repeat expansion
- BDNF (Brain-Derived Neurotrophic Factor): Influences neuronal survival
- APOE: Apolipoprotein E status modifies cognitive decline
- TCF4: Transcription factor associated with disease onset
- HTT haplotypes: Background genetic variation affects mutant HTT toxicity
¶ Genetic Testing and Counseling
Genetic testing for HD is available for multiple purposes:
- At-risk individuals: Those with a family history seeking confirmation
- Prenatal testing: For couples at risk who wish to assess fetal status
- Preimplantation genetic diagnosis (PGD): To prevent transmission to offspring
- Research enrollment: Matching patients to clinical trials
The Huntington's Disease Society of America recommends:
- Genetic counseling: Before and after testing to ensure informed decision-making
- Neurological evaluation: Baseline assessment before testing
- Psychological support: Throughout the testing process
- Follow-up care: Ongoing support regardless of test results
Results require careful interpretation and discussion:
- Positive result: Indicates presence of pathogenic CAG expansion
- Negative result: Normal repeat length (< 26 CAG)
- Intermediate result: 27-35 CAG repeats (not diagnostic but has implications for offspring)
Several approaches are being developed to lower mutant huntingtin protein:
- Tominersen (RG6042): Phase III trials showed dose-dependent HTT reduction but were discontinued due to worsening clinical outcomes
- Other ASOs in development: Targeting specific SNP alleles in combination with mutant HTT
- AAV-delivered RNAi approaches: Preclinical and early clinical stages
- CRISPR-Cas9 gene editing: In preclinical development; potential to permanently correct the mutation
- HSP90 inhibitors: Enhance mutant protein clearance
- Transcriptional modulators: Reduce HTT expression at the RNA level
Current treatments focus on symptom management:
- Chorea management: Tetrabenazine, valbenazine, deutetrabenazine
- Mood stabilization: SSRIs, antipsychotics
- Cognitive support: Environmental modifications, supportive therapies